The caption of Fig. 1 was corrected from “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemiafree survival (c, LFS), and overall survival(d, OS) patients receiving post-transplant cyclophosphamide (PTCy) versus Cyclosporine A (CSA) / methotrexate (MTX)” to “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemia-free survival(c, LFS), and overall survival (d, OS) of patients receiving reduced intensity versus myeloablative conditioning regimen”. The original article has been corrected.

Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (Bone Marrow Transplantation, (2022), 57, 7, (1116-1123), 10.1038/s41409-022-01693-8)

Ciceri F.;
2022-01-01

Abstract

The caption of Fig. 1 was corrected from “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemiafree survival (c, LFS), and overall survival(d, OS) patients receiving post-transplant cyclophosphamide (PTCy) versus Cyclosporine A (CSA) / methotrexate (MTX)” to “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemia-free survival(c, LFS), and overall survival (d, OS) of patients receiving reduced intensity versus myeloablative conditioning regimen”. The original article has been corrected.
File in questo prodotto:
File Dimensione Formato  
s41409-022-01834-z.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 474.5 kB
Formato Adobe PDF
474.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/138239
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact